MENLO PARK, Calif., Sept. 12, 2024 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. (“Oruka” or the “Company”) (Nasdaq: ORKA), a biotechnology company developing novel biologics designed to set a new standard for the treatment of chronic skin diseases, including plaque psoriasis, today announced that
ORKA-001, a novel half-life extended IL-23p19 monoclonal antibody (mAb), first-in-human dosing now expected first quarter 2025 ORKA-002, a novel half-life extended IL-17A/F mAb, first-in-human dosing now expected third quarter 2025 New preclinical data on ORKA-001 to be presented at EADV in
Oruka is advancing a pipeline of potentially best-in-class biologics that aim to offer greater freedom from disease to people with plaque psoriasis and other associated conditions Company on track to advance co-lead programs, ORKA-001 and ORKA-002, into the clinic and show initial pharmacokinetic
Paul Quinlan joins as General Counsel Alan Lada joins as VP of Investor Relations Kristine Ball, President & CEO of Antiva Biosciences, appointed to Board of Directors MENLO PARK, Calif., and WALTHAM, Mass., June 26, 2024 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc.
WALTHAM, Mass., May 29, 2024 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. (“Oruka”), a biotechnology company developing novel biologics designed to set a new standard for the treatment of chronic skin diseases, including plaque psoriasis, today announced that Lawrence Klein, PhD, Chief Executive
Joe Senn, PhD, joins as SVP of Nonclinical Research & Development Rajiv Panwar, PhD, joins as VP and Head of Chemistry, Manufacturing, and Controls Appointments strengthen Oruka’s executive leadership team and support the advancement of the company’s portfolio of potentially best-in-class
Dr. Goncalves, former CMO at Cara Therapeutics, joins Oruka as CMO Eugenia Levi, PharmD, former Head of Global Medical Affairs for Cosentyx at Novartis, also joins as VP, Medical Affairs WALTHAM, Mass., April 24, 2024 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc.
Merger to create a company focused on advancing Oruka’s portfolio of novel biologics that aim to redefine the standard of care for patients with chronic skin diseases Oruka, the third company founded based on assets generated by Paragon Therapeutics, expects to advance ORKA-001 and ORKA-002,